HC Wainwright Issues Pessimistic Forecast for AVBP Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for ArriVent BioPharma to a loss of $1.04 per share from $0.96, and projects a $4.14-per-share loss for full-year 2026.
• Despite the weaker earnings outlook, HC Wainwright maintained a Buy rating and raised its price target to $47. Other analysts remain broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average target of $44.86.
• ArriVent reported a quarterly loss of $1.05 per share, missing the $0.99 consensus estimate. Shares opened at $30, while the company continues to operate as a clinical-stage biotechnology firm developing targeted cancer therapies.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for ArriVent BioPharma in a research note issued on Monday, August 17th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.04) per share for the quarter, down from their prior forecast of ($0.96). HC Wainwright has a "Buy" rating and a $47.00 price objective on the stock. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($3.96) per share. HC Wainwright also issued estimates for ArriVent BioPharma's Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.14) EPS, Q1 2027 earnings at ($1.11) EPS, Q2 2027 earnings at ($1.16) EPS, Q3 2027 earnings at ($1.04) EPS and Q4 2027 earnings at ($0.93) EPS.

AVBP has been the subject of several other research reports. BTIG Research reiterated a "buy" rating and issued a $42.00 target price on shares of ArriVent BioPharma in a report on Thursday, August 13th. Cantor Fitzgerald restated an "overweight" rating on shares of ArriVent BioPharma in a research note on Friday, May 22nd. Guggenheim restated a "buy" rating and set a $45.00 price target on shares of ArriVent BioPharma in a research report on Thursday, August 13th. Truist Financial lifted their price objective on ArriVent BioPharma from $43.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, May 29th. Finally, Citigroup cut their price objective on ArriVent BioPharma from $43.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, ArriVent BioPharma has an average rating of "Moderate Buy" and an average target price of $44.86.

ArriVent BioPharma Stock Performance

Shares of AVBP stock opened at $30.00 on Wednesday. The firm has a market cap of $1.40 billion, a P/E ratio of -8.29 and a beta of 1.36. The firm's 50 day moving average price is $31.75 and its 200-day moving average price is $27.95. ArriVent BioPharma has a one year low of $17.00 and a one year high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.06).

Institutional Trading of ArriVent BioPharma

Several hedge funds have recently modified their holdings of AVBP. Dimensional Fund Advisors LP raised its holdings in shares of ArriVent BioPharma by 758.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 126,525 shares of the company's stock valued at $2,918,000 after purchasing an additional 111,782 shares in the last quarter. Tema ETFs LLC acquired a new position in shares of ArriVent BioPharma during the second quarter worth $1,981,000. Vivo Capital LLC purchased a new position in ArriVent BioPharma in the first quarter valued at $20,438,000. Affinity Asset Advisors LLC increased its holdings in ArriVent BioPharma by 16.7% in the first quarter. Affinity Asset Advisors LLC now owns 175,000 shares of the company's stock valued at $4,037,000 after buying an additional 25,000 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new stake in ArriVent BioPharma in the first quarter valued at $1,159,000. 9.48% of the stock is currently owned by institutional investors and hedge funds.

More ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright raised its price target for ArriVent BioPharma from $44 to $47 while maintaining a Buy rating. The target implies substantial potential appreciation from the referenced $30 share price, signaling confidence in the company’s long-term prospects. HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma
• Neutral Sentiment: HC Wainwright projected continued losses through 2027, including EPS of ($1.11) in Q1 2027, ($1.16) in Q2, ($1.04) in Q3 and ($0.93) in Q4. The firm estimates a full-year 2027 loss of ($4.24), underscoring that ArriVent remains an early-stage biotechnology company reliant on future clinical and commercial progress.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to a loss of ($1.04) from ($0.96), reduced its Q4 estimate to ($1.07) from ($0.99), and cut its FY2026 forecast to a loss of ($4.14) from ($3.86). These revisions indicate higher expected near-term expenses or slower progress toward profitability and are a negative factor for the stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source